Objective: To determine if blastomere biopsy affects the rate of blastulation as compared to intact embryos.
Study Design: Retrospective age-matched cohort study.
Results: Forty-one patients with 41 in vitro fertilization (IVF) cycles and 329 embryos who under- went cleavage-stage biopsy with preimplantation genet- ic screening using array com- parative genomic hybridiza- tion were compared to 41 IVF cycles with 352 embryos eligible for biopsy but who did not undergo biopsy January 2011-July 2013. The proportion of embryos that developed to the blastocyst stage was significantly lower in the case group than in the control group (46.5% vs. 59.9%; p=0.0134). This was most evident in the age group >35 years old (43.2% vs. 58.8%; p=0.035). No significant difference was detected in proportions that developed to fully expanded' or hatching blastulation between cases and controls (28.0% vs. 24.4%, p=0.56). There was a statistically .significant difference in the proportion of euploid embryos available for transfer when comparing day 3 vs. day 5 biopsy (20.9% vs. 13.1%, p=0.0003).
Conclusion: Cleavage stage biopsy for genetic testing lowers the overall proportion of embryos that develop to the blastocyst stage by 25% (from 59.9% to 46.5%). When compared to trophectoderm biopsy, cleavage stage biopsy allows for a larger cohort of euploid embryos to be available for selection and transfer.
Download full-text PDF |
Source |
---|
Alzheimers Dement
December 2024
Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
Introduction: Neuropsychiatric symptoms (NPSs) are common in dementia with Lewy bodies (DLB) but their neurobiological mechanisms are poorly understood.
Methods: NPSs and cognition were assessed annually in participants (DLB n = 222; Alzheimer's disease [AD] n = 125) from the European DLB (E-DLB) Consortium, and plasma phosphorylated tau-181 (p-tau181) and p-tau231 concentrations were measured at baseline.
Results: Hallucinations, delusions, and depression were more common in DLB than in AD and, in a subgroup with longitudinal follow-up, persistent hallucinations and NPSs were associated with lower p-tau181 and p-tau231 in DLB.
J Thorac Oncol
December 2024
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Introduction: Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555).
Methods: This is a single center, pilot study of patients with clinical stage IA-IIIA NSCLC (AJCC 8th edition) harboring an activating EGFR mutation (Exon 19 deletion, L858R) (NCT04816838).
Exp Neurol
December 2024
Department of Molecular Biology and Genetics, Faculty of Science, Istanbul University, Istanbul, Turkiye. Electronic address:
Growing evidence reveals that microglia activation and neuroinflammatory responses trigger cell loss in the brain. Histamine is a critical neurotransmitter and promotes inflammatory responses; thus, the histaminergic system is a potential target for treating neurodegenerative processes. JNJ-7777120, a histamine H4 receptor (HR) antagonist, has been shown to alleviate inflammation, brain damage, and behavioral deficits effectively, but there is no report on its role in brain trauma.
View Article and Find Full Text PDFInt Immunopharmacol
December 2024
Department of Critical Care Medicine, the First Affiliated Hospital of Jinan University, Guangzhou 510632, Guangdong, China. Electronic address:
Previous studies demonstrated that dexmedetomidine (Dex) posttreatment aggravated myocardial dysfunction and reduced survival in septic mice. Yet, whether Dex elicits similar effects in septic patients as defined by Sepsis-3 remains unknown. This study sought to assess the effects of Dex-based sedation on mortality and cardiac dysfunction in septic patients defined by Sepsis-3 and to further reveal the mechanisms in septic rats.
View Article and Find Full Text PDFHematol Oncol
January 2025
Département d'Hématologie, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!